Saturday 17 October 2026
Export MIRA’s income statement to Excel — free account
MIRA Pharmaceuticals, Inc.
MIRA Healthcare Drug Manufacturers General
In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.
0.63
0.03
−4.55%
Follow MIRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Current Ratio |
15.75 | 3.99 | 8.70 | 0.36 | 2.57 | 0.04 |
Net Debt/EBITDA |
1.05 | 0.35 | 0.54 | 0.03 | 1.17 | (1.28) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 15.51% | 8.74% | 318.02% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.22) | 0.13 | (1.45) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.15 | 0.71 | 0.38 | 0.79 | 0.63 | 1.00 |
Capex/Depreciation |
— | — | 0.00 | — | — | — |
Interest Coverage |
— | 48.39 | (2.47) | (684.26) | (176.41) | (338.00) |
| (508.28%) | (238.90%) | (634.30%) | (847.73%) | (197.93%) | 0.00% | |
| (456.59%) | (199.93%) | (413.86%) | (335.04%) | (128.65%) | 0.00% | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(308.99%) | (362.81%) | (278.65%) | 806.10% | (126.85%) | 78.25% |
Average Days of Receivables |
— | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(0.20) | (0.36) | (0.33) | (0.32) | (0.09) | 0.00 |
Cash per Share |
0.47 | 0.18 | 0.33 | 0.02 | 0.19 | 0.00 |
Shareholders Equity per Share |
0.44 | 0.14 | 0.31 | (0.03) | 0.15 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.44 | 0.14 | 0.31 | (0.03) | 0.15 | 0.00 |
Free Cash Flow |
(4.66) | (5.56) | (4.53) | (5.60) | (1.38) | (0.07) |
Working Capital |
10.36 | 2.16 | 4.30 | (0.88) | 1.72 | (0.09) |
Net Current Asset Value |
10.36 | 2.16 | 4.30 | (0.96) | 1.72 | (0.09) |
| Other line items | ||||||
Quick Ratio |
15.71 | 3.92 | 8.27 | 0.26 | 2.57 | 0.04 |
Depreciation/Fixed assets |
— | — | 0.00 | 0.00 | — | — |
Cash ROIC |
(21.76%) | (110.49%) | (50.49%) | 4,999.82% | (25.66%) | (216.56%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.20) | (0.36) | (0.33) | (0.32) | (0.09) | 0.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
0.43 | 0.63 | 0.73 | — | — | — |
Average Assets |
7.01 | 3.93 | 2.90 | 2.11 | 1.69 | — |
Average Common Equity |
6.30 | 3.29 | 1.89 | 0.83 | 1.10 | — |
Columns are period end dates